Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ELANCO'S SECOND DERMATOLOGY PRODUCT APPROVAL IN LESS THAN 18 MONTHS IN THE ESTIMATED $1.3 BILLION U.S. CANINE DERMATOLOGY MARKET BEFRENA HAS BEEN SHOWN TO BE EFFECTIVE FOR TREATMENT OF DOGS OF ANY AGE AGAINST CANINE ATOPIC DERMATITIS AND ALLERGIC DERMATITIS FOR 6 TO 8 WEEKS OF TREATMENT, AS NEEDED USDA APPROVAL OFBEFRENA REINFORCES ELANCO'S COMMITMENT TO GOING BEYOND TO DELIVER DIFFERENTIATED, HIGH-QUALITY PRODUCTS IN EVERY KEY THERAPEUTIC AREA, BOLSTERING ITS LEADERSHIP IN CANINE DERMATOLOGY AND MONOCLONAL ANTIBODIES (MABS) CANINE ALLERGIC ANDATOPIC DERMATITIS IS A WIDESPREAD CONCERN AMONGST VETERINARIANS, WITH DATA REVEALING THAT NEARLY 98% OF VETS SAY THEY ROUTINELY TREAT DOGS FOR ATOPIC DERMATITIS AND THAT ITCHY DOGS MAKE UP NEARLY 20% OF THEIR PATIENT POPULATIONI INDIANAPOLIS, IND., DEC. 31, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED ITS LATEST ENTRY INTO THE RAPIDLY GROWING CANINE DERMATOLOGY SPACE WITH THE U.S. DEPARTMENT OF AGRICULTURE (USDA) APPROVAL OF BEFRENA (TIRNOVETMAB), A NEW ANTI-IL31 MONOCLONAL ANTIBODY (MAB) INJECTION TARGETING CANINE ALLERGIC AND ATOPIC DERMATITIS.

ELANCO RECEIVES USDA APPROVAL FOR BEFRENA (TIRNOVETMAB), A NEW ANTI-IL31 MONOCLONAL ANTIBODY INJECTION TARGETING CANINE ALLERGIC AND ATOPIC DERMATITIS

CONDITIONAL APPROVAL MARKS ELANCO'S THIRD NEW WORLD SCREWWORM TREATMENT OPTION FOR COMPANION ANIMALS, PROVIDING MULTIPLE TREATMENT SOLUTIONS PRIOR TO FLY BEING DETECTED IN THE U.S. FDA'S CONDITIONAL APPROVAL OFCREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) IS THE FIRST FOR COMPANION ANIMALS AGAINST NEW WORLD SCREWWORM ACTION FOLLOWS PREVIOUS EMERGENCY USE AUTHORIZATIONS GRANTED BY THE FDA FORCREDELIO (LOTILANER) AND CREDELIO CAT (LOTILANER) TO TREAT NEW WORLD SCREWWORM IN DOGS AND CATS, RESPECTIVELY CREDELIO QUATTRO/CREDELIO QUATTRO-CA1 PROVIDES THE BROADEST PARASITE COVERAGE OF ITS KIND* - COVERING SEVEN TYPES OF PARASITES INCLUDING TICKS, FLEAS, HEARTWORM DISEASE, ROUNDWORMS, HOOKWORMS, TAPEWORMS, AND NOW NEW WORLD SCREWWORM** PUBLISHED LITERATURE SHOWSLOTILANER, AN ACTIVE INGREDIENT IN CREDELIO QUATTRO-CA1, HAS A REASONABLE EXPECTATION OF EFFECTIVENESS FOR THE TREATMENT OF INFESTATIONS CAUSED BY NEW WORLD SCREWWORMI INDIANAPOLIS , DEC. 18, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED IT HAS RECEIVED CONDITIONAL APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) FOR THE TREATMENT OF INFESTATIONS CAUSED BY NEW WORLD SCREWWORM LARVAE (MYIASIS) IN DOGS. THIS IS THE FIRST FDA CONDITIONAL APPROVAL FOR A COMPANION ANIMAL PRODUCT TO TREAT NEW WORLD SCREWWORM.

ELANCO'S CREDELIO QUATTRO-CA1 (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) RECEIVES FIRST FDA CONDITIONAL APPROVAL FOR TREATMENT OF NEW WORLD SCREWWORM IN DOGS

DETAILS THREE-YEAR OUTLOOK WITH ANNUAL MID-SINGLE DIGIT TOP-LINE ORGANIC CONSTANT CURRENCY GROWTH DRIVEN BY A CONSISTENT FLOW OF HIGH-IMPACT INNOVATION, HIGH-SINGLE DIGIT ADJUSTED EBITDA GROWTH AND LOW DOUBLE-DIGIT ADJUSTED EPS GROWTH, ALL STARTING IN 2026. EXPECTS FURTHER NET LEVERAGE RATIO IMPROVEMENT TO

ELANCO INVESTOR DAY DEFINES NEW ERA AS SUSTAINABLE GROWTH COMPANY

MELBOURNE, AUSTRALIA , NOV. 26, 2025 /PRNEWSWIRE/ -- NEURIZON THERAPEUTICS LIMITED (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("NEURIZON" OR "THE COMPANY"), A CLINICAL-STAGE BIOTECH COMPANY DEDICATED TO ADVANCING INNOVATIVE TREATMENTS FOR NEURODEGENERATIVE DISEASES, IS PLEASED TO ANNOUNCE THE APPOINTMENT OF MS JUSTINE CONWAY AS A BOARD OBSERVER. MS CONWAY CURRENTLY SERVES AS GLOBAL HEAD OF BUSINESS DEVELOPMENT AT ELANCO ANIMAL HEALTH ("ELANCO") (NYSE: ELAN) AND WILL PARTICIPATE IN NEURIZON'S BOARD ACTIVITIES AS ELANCO'S DESIGNATED REPRESENTATIVE.

ELANCO EXECUTIVE APPOINTED AS NEURIZON'S BOARD OBSERVER

EUA TO TREAT CATS FOR NWS ISSUED PRIOR TO FLY BEING DETECTED IN THE U.S.; ACTION PREPARES VETERINARIANS AND PET OWNERS WITH TREATMENT OPTIONS FIRST U.S. FOOD AND DRUG ADMINISTRATION EMERGENCY USE AUTHORIZATION (EUA) GRANTED FOR NEW WORLD SCREWWORM IN CATS, REINFORCING ELANCO'S LEADERSHIP IN FELINE INNOVATION ACTION REINFORCES THE FDA'S COMMITMENT TO ACT SWIFTLY AGAINST EMERGING ANIMAL HEALTH THREATS SCIENTIFIC STUDIES SHOWEDCREDELIO CAT MAY BE EFFECTIVE IN TREATING NEW WORLD SCREWWORM IN CATSI,II PREVENTING OPEN WOUNDS THROUGH EFFECTIVE FLEA AND TICK CONTROL IS CRITICAL IN PROTECTING PETS FROMNWS INDIANAPOLIS , NOV. 21, 2025 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED IT HAS RECEIVED EMERGENCY USE AUTHORIZATION (EUA) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CREDELIO CAT (LOTILANER) TO TREAT NEW WORLD SCREWWORM (NWS) INFESTATIONS IN CATS. THIS AUTHORIZATION REPRESENTS THE FIRST EUA GRANTED BY THE FDA FOR NEW WORLD SCREWWORM TREATMENT IN FELINES.

ELANCO'S CREDELIO CAT (LOTILANER) RECEIVES FIRST FDA EMERGENCY USE AUTHORIZATION (EUA) FOR TREATMENT OF NEW WORLD SCREWWORM (NWS) IN CATS

INDIANAPOLIS , NOV. 20, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN UPCOMING INVESTOR CONFERENCES. ON WEDNESDAY, DECEMBER 3, JEFF SIMMONS, PRESIDENT AND CEO, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE AT 12:30 P.M.

ELANCO TO PARTICIPATE IN THE UPCOMING INVESTOR CONFERENCES

ALLOY PARTNERS, ELANCO AND OTHER CORPORATE PARTNERS JOIN FORCES TO DEVELOP NEW VENTURE STUDIO INDIANAPOLIS , NOV. 13, 2025 /PRNEWSWIRE/ -- ALLOY PARTNERS TODAY ANNOUNCED THE LAUNCH OF ONEHEALTH STUDIO, A FIRST-OF-ITS-KIND VENTURE STUDIO DESIGNED SPECIFICALLY TO CREATE AND SCALE NEW COMPANIES AT THE CONVERGENCE OF ANIMAL, PLANT AND HUMAN HEALTH IN PARTNERSHIP WITH ELANCO ANIMAL HEALTH (NYSE: ELAN). LOCATED IN THE ONEHEALTH INNOVATION DISTRICT AT ELANCO'S NEW GLOBAL HEADQUARTERS IN INDIANAPOLIS, THE STUDIO WILL UNITE RESEARCH INSTITUTIONS, INVESTORS, CORPORATE PARTNERS AND ENTREPRENEURS TO ACCELERATE THE NEXT GENERATION OF INNOVATION AND LAUNCH NEW STARTUPS BASED IN INDIANA.

ALLOY PARTNERS LAUNCHES ONEHEALTH STUDIO TO CREATE STARTUPS AT THE CONVERGENCE OF ANIMAL, PLANT AND HUMAN HEALTH

RAISING FULL YEAR OUTLOOK AND INNOVATION TARGET, IMPROVING YEAR-END NET LEVERAGE RATIO TARGET THIRD QUARTER 2025 FINANCIAL RESULTS: REVENUE OF $1,137 MILLION, AN INCREASE OF 10% YEAR-OVER-YEAR; 9% ORGANIC CONSTANT CURRENCY GROWTH REPORTED NET LOSS OF $34 MILLION, ADJUSTED NET INCOME OF $94 MILLION ADJUSTED EBITDA OF $198 MILLION; ADJUSTED EBITDA MARGIN OF 17.5% REPORTED EPS OF $(0.07), ADJUSTED EPS OF $0.19 NET LEVERAGE RATIO OF 3.7X ADJUSTED EBITDA FULL YEAR 2025 GUIDANCE: RAISING REVENUE GUIDANCE TO $4,645 MILLION TO $4,670 MILLION; EXPECT ACCELERATING ORGANIC CONSTANT CURRENCY REVENUE GROWTH OF 6% TO 6.5% VS. 3% IN 2024 RAISING 2025 INNOVATION REVENUE TARGET BY $100 MILLION AT THE MIDPOINT OF THE RANGE TO $840 TO $880 MILLION REPORTED NET LOSS OF $56 MILLION TO $41 MILLION, RAISING GUIDANCE FOR ADJUSTED EBITDA TO $880 MILLION TO $900 MILLION REPORTED LOSS PER SHARE OF $0.11 TO $0.08, RAISING GUIDANCE FOR ADJUSTED EPS TO $0.91 TO $0.94 2025 YEAR-END NET LEVERAGE RATIO TARGET IMPROVED TO 3.7X TO 3.8X, ENABLED BY YEAR-TO-DATE EXECUTION AND DISCIPLINED WORKING CAPITAL MANAGEMENT INDIANAPOLIS , NOV. 5, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2025, PROVIDED GUIDANCE FOR THE FOURTH QUARTER OF 2025, AND UPDATED GUIDANCE FOR THE FULL YEAR 2025.

ELANCO ANIMAL HEALTH REPORTS THIRD QUARTER 2025 RESULTS

FDA APPROVES EXPANDED CREDELIO QUATTRO AND CREDELIO LABELS TO INCLUDE PREVENTION OF LYME DISEASE AS A RESULT OF KILLING BLACK-LEGGED TICKS (LXODES SCAPULARIS) AND PROTECTION AGAINST THE LONGHORNED TICK (HAEMAPHYSALIS LONGICORNIS), WHICH IS RAPIDLY SPREADING, NOW REACHING 22 STATES.I THE COMPANION ANIMAL AND PARASITE COUNCIL TRACKER SHOWS MORE THAN 422,000 CASES OF LYME DISEASE IN DOGS SO FAR THIS YEAR,II SURPASSING THE TOTAL NUMBER OF ANNUAL CASES SEEN IN ALL OF 2019.III ELANCO CONTINUES TO GO BEYOND FOR VETERINARIANS AND PET OWNERS, PROVIDING EVEN MORE COMPREHENSIVE PROTECTION AGAINST SOME OF THE MOST CONCERNING TICKS. INDIANAPOLIS, IND.

ELANCO ANNOUNCES EXPANSION OF CREDELIO QUATTRO (LOTILANER, MOXIDECTIN, PRAZIQUANTEL, AND PYRANTEL CHEWABLE TABLETS) AND CREDELIO (LOTILANER) LABELS, OFFERING PROTECTION AGAINST LYME DISEASE AND AN EMERGING TICK SPECIES

EUA TO TREAT DOGS FOR NWS ISSUED PRIOR TO FLY BEING DETECTED IN THE U.S.; ACTION PREPARES VETERINARIANS AND PET OWNERS WITH TREATMENT OPTIONS FIRST FDA EMERGENCY USE AUTHORIZATION (EUA) EVER GRANTED FOR NWS IN DOGS ACTION REINFORCES AGENCY'S COMMITMENT TO PROVIDING TREATMENT OPTIONS FOR NWS IN ADVANCE OF THE FLY BEING DETECTED IN THE U.S. PUBLISHED LITERATURE SHOWED CREDELIO MAY BE EFFECTIVE IN TREATING NWS IN DOGSI PREVENTING OPEN WOUNDS THROUGH EFFECTIVE FLEA AND TICK CONTROL IS CRITICAL IN PROTECTING PETS FROM NWS INDIANAPOLIS , OCT. 24, 2025 /PRNEWSWIRE/ -- ELANCO ANIMAL HEALTH INCORPORATED (NYSE: ELAN) TODAY ANNOUNCED IT HAS RECEIVED EMERGENCY USE AUTHORIZATION (EUA) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR CREDELIO (LOTILANER) TO TREAT NEW WORLD SCREWWORM (NWS) INFESTATIONS IN DOGS. THIS IS THE FIRST EUA EVER GRANTED BY THE AGENCY FOR NWS IN DOGS.

ELANCO'S CREDELIO (LOTILANER) RECEIVES FIRST EVER FDA EMERGENCY USE AUTHORIZATION (EUA) AGAINST NEW WORLD SCREWWORM (NWS) IN DOGS

INDIANAPOLIS , OCT. 16, 2025 /PRNEWSWIRE/ --ELANCO ANIMAL HEALTH, INC. (NYSE: ELAN) WILL HOST AN INVESTOR DAY ON TUESDAY, DECEMBER 9, 2025, FROM APPROXIMATELY 9 A.M. TO 12 P.M.

Elanco Animal Health Incorporated

ELAN

Price

Financial Reports

No items found.

Press Releases

Elanco Animal Health Incorporated

ELAN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ELAN